US woes hurt Sun's Q2 profits as it makes fresh charges against Taro
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has reported an 11.5% decline in net profits to Rs4.54 billion ($95.8 million) for the second quarter ended September 30th, hurt by US FDA action against its US subsidiary over certain current good manufacturing practice (cGMP) violations.